New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: gelatin   ethylcellulose dispersion type b ink black 10a2 iron oxide black iron oxide red methacrylic acid copolymer polysorbate 80 purified talc sugar spheres titanium dioxide   triethyl citrate - indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

United States - English - NLM (National Library of Medicine)

ritedose pharmaceuticals, llc - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - 1.1 maintenance treatment of asthma budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. limitations of use: - budesonide inhalation suspension is not indicated for the relief of acute bronchospasm. the use of budesonide inhalation suspension is contraindicated in the following conditions: - primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see warnings and precautions (5.3), description (11), adverse reactions (6.2)] . 8.1 pregnancy risk summary there are no adequate well-controlled studies of budesonide inhalation suspension in pregnant women. however, there are published studies on the use of budesonide, the active ingredient in budesonide inhalation suspension, in pregnant women. in animal reproduction studies, budesonide, administered by the su

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - budesonide - powder for inhalation - 400 microgram(s) - glucocorticoids; budesonide

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - budesonide - powder for inhalation - 200 microgram(s) - glucocorticoids; budesonide

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 200 mcg/dose - budesonide - budesonide - bronchial asthma.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 100 mcg/dose - budesonide - budesonide - bronchial asthma.

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.

Israel - English - Ministry of Health

novartis israel ltd - budesonide - capsules - budesonide 200 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

Israel - English - Ministry of Health

novartis israel ltd - budesonide - capsules - budesonide 400 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - budesonide, quantity: 9 mg - tablet, modified release - excipient ingredients: stearic acid; lecithin; microcrystalline cellulose; hyprolose; lactose monohydrate; silicon dioxide; magnesium stearate; methacrylic acid copolymer; purified talc; titanium dioxide; triethyl citrate - cortiment prolonged-release tablets are indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis (uc) where 5-asa treatment is not sufficient or not tolerated.